Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of ARN-75039 Tablets vs Capsules in Healthy Volunteers
NCT06911242Phase 1Completed
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ARN-75039 in Lassa fever (2 arms). Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at 168 hours, Area Under the Curve from Time Zero to 24 Hours and 6 more. Started Feb 2025; status: completed.
02
Drugs
ARN-75039
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT06911242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911242.